It's hard to value, because it's still a growth company.From the...

It's hard to value, because it's still a growth company.
From the point of view of trying to do a price to EBITDA valuation for a business, you could argue that with all expenses you'd be expected 30 ish percent margin plus corporate costs... So from an EBITDA standpoint you'd be looking at 10 to 20 million. price to EBITDA of 6 to 8 times brings you to 60 to 160 million....
Having said that, if a company has grown from 1 million revenuve to 100 million revenue in three to four years, and is a strategic acquisition for another company, the same company would be much more likely valued much much higher... Something closer to Eargo's current price than Nuheara's current price...

So the short answer, if we are building up towards 100 million revenue by 2023, with added growth in the OTC hearing aid approved by FDA, this is most likely closer to a billion dollars than its current share price.